Navigation Links
Dyadic International Reports 2012 Third Quarter Financial Results
Date:11/8/2012

JUPITER, Fla., Nov. 8, 2012 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, today announced financial results for the quarter ended September 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Business OutlookDyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "As we continue down the road toward a profitable 2012, recent events have further increased our confidence in Dyadic's near-term growth prospects."

"Dyadic's research team in the Netherlands has experienced a string of successes over the last few months in using Dyadic's patented and proprietary C1 technology to conduct research projects funded by third parties in the key areas of biofuels, animal health and nutrition, food and biopharmaceuticals. In particular, the novel ability of Dyadic's C1 white strain to produce purer cost-efficient enzymes, is proving to be an additional valuable tool in attracting research and licensing partners. Some of these projects are currently in the process of being expanded which will generate additional R&D revenue and further increase the likelihood of increased future license revenue to Dyadic. The greater than two-fold increase in deferred research and development obligation in the third quarter as compared to the previous quarter as listed in our third quarter financial statements represents a growing backlog of research revenue which will be recognized in subsequent quarters as this research is performed. This shows that research and development activities are actually still growing even though the related revenue will not be recognized until future periods."

"Adding to Dyadic's recent research accomp
'/>"/>

SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
2. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
3. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
4. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
5. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
6. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
7. Boston Childrens Hospital announces international genomics competition winner
8. International Oncology Innovators Meeting in Hamburg
9. Jaipal Reddy, Honble Minister of Science and Technology & Earth Sciences, Inaugurates the International Bioenergy Summit in Delhi
10. GDS International Confirms the Attendance of Top Executives to its Eleventh North American Healthcare Summit in December
11. PAREXEL International to Present at Morningstar Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ... remaining soft. , This solid economic news is having a ...
(Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... , - German Chemical Parks ... The number of employees in German chemical parks ... In this same period, the number of,companies doing business at ... today by Dr. Klaus-Dieter Juszak, Chairman of the,German Sector Group ...
... EXPANSION INTO EUROPE AND STRENGTHENS ITS SENIOR MANAGEMENT ... 12 OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), ... for clinical trials, today announced that it has strengthened ... of Dr. Wolfgang Summa. As Executive Vice President, Europe ...
... today that it has acquired from biotechnology company Antisoma ... film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) ... United States for use as a second-line therapy to ... pleased to add Oforta to our existing oncology portfolio, ...
Cached Biology Technology:10,000 New Jobs, Investments Increased 210,000 New Jobs, Investments Increased 3OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 2OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 3Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 2Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 3
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... -- Today, oxygen takes up a hefty portion of Earth,s ... air we breathe. However, very early in Earth,s history, O2 ... in the turbulent mix of primordial gases. It wasn,t until ... when oxygen made any measurable dent in the atmosphere, stimulating ...
... salt for all seasons. It turns up not only in ... coral reefs and even in pearls. The compound exists ... it is not clear what determines which variant an organism ... A team of researchers led by LMU geobiologist Dr. Azizur ...
... at risk for a certain form of colon and other ... surviving or even avoiding the diseases, thanks to a new ... Hospital. The Intermountain Heathcare group of scientists used sophisticated ... identify patients who may have Lynch syndrome, an inherited cancer ...
Cached Biology News:MIT: Oxygen's watery past 2MIT: Oxygen's watery past 3New process that may save lives of cancer patients is effective and significantly less costly 2New process that may save lives of cancer patients is effective and significantly less costly 3
RAT ANTI RAT RT1Au (CLASS I POLYMORPHIC) Immunogen: AO lymphoid cells...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
MOUSE ANTI SIMIAN VIRUS 5:FITC Immunogen: Simian virus 5...
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
Biology Products: